Jiangsu Hengrui Medicine (SHA:600276, HKG:1276) obtained the approval of China's drug regulator to start clinical trials for emmaxtinib sulfate tablets and SHR0302 alkaline gel for the treatment of vitiligo.
The applied indication is emmaxtinib sulfate as monotherapy or in combination with SHR0302 alkaline gel, according to a filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments